icad inc. (ICAD): Price and Financial Metrics

icad inc. (ICAD): $1.67

0.06 (+3.73%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

ICAD Price/Volume Stats

Current price $1.67 52-week high $3.97
Prev. close $1.61 52-week low $1.05
Day low $1.60 Volume 168,725
Day high $1.77 Avg. volume 505,857
50-day MA $1.62 Dividend yield N/A
200-day MA $1.82 Market Cap 44.01M

ICAD Stock Price Chart Interactive Chart >

ICAD POWR Grades

  • Sentiment is the dimension where ICAD ranks best; there it ranks ahead of 82.52% of US stocks.
  • ICAD's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • ICAD ranks lowest in Momentum; there it ranks in the 9th percentile.

ICAD Stock Summary

  • ICAD has a higher market value than only 13.41% of US stocks; more precisely, its current market capitalization is $34,098,185.
  • Revenue growth over the past 12 months for ICAD INC comes in at -24.1%, a number that bests just 11.37% of the US stocks we're tracking.
  • The volatility of ICAD INC's share price is greater than that of 86.59% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to ICAD INC, a group of peers worth examining would be NURO, SHPW, SRTS, RPID, and TACT.
  • ICAD's SEC filings can be seen here. And to visit ICAD INC's official web site, go to www.icadmed.com.

ICAD Valuation Summary

  • In comparison to the median Healthcare stock, ICAD's price/sales ratio is 5.88% lower, now standing at 1.6.
  • ICAD's price/sales ratio has moved down 19.7 over the prior 243 months.

Below are key valuation metrics over time for ICAD.

Stock Date P/S P/B P/E EV/EBIT
ICAD 2023-11-03 1.6 1.3 -3.2 -1.9
ICAD 2023-11-02 1.6 1.3 -3.1 -1.8
ICAD 2023-11-01 1.4 1.1 -2.7 -1.4
ICAD 2023-10-31 1.4 1.1 -2.7 -1.4
ICAD 2023-10-30 1.4 1.1 -2.7 -1.4
ICAD 2023-10-27 1.4 1.1 -2.7 -1.4

ICAD Growth Metrics

    The year over year price growth rate now stands at -81.39%.
  • Its 5 year net cashflow from operations growth rate is now at -29.84%.
  • Its 3 year net income to common stockholders growth rate is now at -39.08%.
ICAD's revenue has moved down $4,788,000 over the prior 15 months.

The table below shows ICAD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 29.262 -11.207 -14.707
2022-06-30 32.267 -10.84 -12.985
2022-03-31 32.518 -10.294 -13.147
2021-12-31 33.638 -9.408 -11.245
2021-09-30 36.282 -8.763 -8.702
2021-06-30 34.05 -8.989 -8.323

ICAD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ICAD has a Quality Grade of C, ranking ahead of 38.2% of graded US stocks.
  • ICAD's asset turnover comes in at 0.555 -- ranking 80th of 186 Medical Equipment stocks.
  • TTOO, IRMD, and DYNT are the stocks whose asset turnover ratios are most correlated with ICAD.

The table below shows ICAD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.555 0.714 -0.737
2021-03-31 0.561 0.728 -0.590
2020-12-31 0.628 0.719 -1.587
2020-09-30 0.653 0.736 -1.431
2020-06-30 0.695 0.752 -1.339
2020-03-31 0.769 0.754 -1.337

ICAD Price Target

For more insight on analysts targets of ICAD, see our ICAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1.31 (Strong Buy)

icad inc. (ICAD) Company Bio


iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.


ICAD Latest News Stream


Event/Time News Detail
Loading, please wait...

ICAD Latest Social Stream


Loading social stream, please wait...

View Full ICAD Social Stream

Latest ICAD News From Around the Web

Below are the latest news stories about ICAD INC that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive Returns

As the Street realizes that we're in the early stages of the business cycle, penny stocks should boom.

Larry Ramer on InvestorPlace | November 22, 2023

iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution

Offering radiology the most complete breast health solution, including breast density assessment, breast cancer detection, and thorough risk evaluation, including lifetime, genetic, and short-term 1- or 2-year AI-riskPartnership to expand access to ProFound Breast Health Suite and CancerIQ’s platform to benefit patients across thousands of facilities NASHUA, N.H. and CHICAGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-dete

Yahoo | November 20, 2023

This iCAD Insider Increased Their Holding In The Last Year

Insiders were net buyers of iCAD, Inc.'s ( NASDAQ:ICAD ) stock during the past year. That is, insiders bought more...

Yahoo | November 16, 2023

iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, President and Chief Executive Officer and Eric Lonnqvist, Chief Financial Officer, will participate at the 14th Annual Craig-Hallum Alpha Select Conference on Thursday, November 16th. The conference will be held at the Sheraton New York Times Square in Ne

Yahoo | November 14, 2023

iCAD Reports Financial Results for Third Quarter Ended September 30, 2023

Company to host conference call and webcast today at 4:30 PM ETNASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023. Highlights: Completed sale of Xoft, its therapy business line, to Elekta thereby enabling the Company to focus exclusi

Yahoo | November 13, 2023

Read More 'ICAD' Stories Here

ICAD Price Returns

1-mo 26.52%
3-mo -29.39%
6-mo 28.46%
1-year -2.91%
3-year -83.25%
5-year -61.52%
YTD -8.74%
2022 -74.58%
2021 -45.45%
2020 69.88%
2019 110.00%
2018 7.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!